At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 500 enrolled

Drug / intervention

MK0364drug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00109148

NCT00109148Phase 2Completed

A Study to Assess the Safety and Efficacy of MK0364 in Obese Patients

Merck Sharp & Dohme LLC·interventional·Posted Apr 25, 2005·Updated Sep 9, 2015

In Brief

A Phase 2 clinical trial evaluating MK0364 for Obesity. Completed, enrolled 500 participants.

The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with obesity (considerably overweight).

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsObesity

Countries--

Collaborators--

Phase 2CompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJul 2004

Primary CompletionJan 2005

Study CompletionFeb 2005

First PostedApr 2005

TodayJul 2026

First PostedApr 25, 2005

Enrollment StartJul 1, 2004

Primary CompletionJan 1, 2005

Study CompletionFeb 1, 2005

TodayJul 2, 2026

Enrollment to primary: 6 monthsPosted 21.2 years ago

MK0364drug